Research Progress of Celastrol in Obesity / 中国药学杂志
Chinese Pharmaceutical Journal
; (24): 293-297, 2020.
Article
en Zh
| WPRIM
| ID: wpr-857774
Biblioteca responsable:
WPRO
ABSTRACT
Obesity is a kind of metabolic disease, which is a major risk factor of heart disease, diabetes mellitus and cancer. In recent years, the US Food and Drug Administration (FDA) has approved a stand of drugs treatment for obesity, including sibutramine, orlistat, belviq and so on,however, side effects may occur after long-term using. Celastrol is a class of pentacyclic triterpenoids extracted from the roots of Tripterygium wilfordii Hook F. It has been found that celastrol has the pharmacological activities of increasing leptin sensitivity, increasing fat metabolism, inhibiting the formation of lipocyte and inhibiting chronic inflammation in obesity animals. This overview summarizes the related mechanisms of celastrol on treatment of obesity to provide enlightenments for its further study.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Risk_factors_studies
Idioma:
Zh
Revista:
Chinese Pharmaceutical Journal
Año:
2020
Tipo del documento:
Article